ERBB2 and breast cancer: Another meta-analysis, which included 11,049 patients, demonstrated that carboplatin, combined with dual HER2 blockade (pertuzumab + trastuzumab) plus docetaxel, was more effective than the same regimen without carboplatin in neoadjuvant treatment for HER2-positive breast cancer [63].